Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Average Rating of “Hold” from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) have received an average recommendation of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Thirteen investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.25.

Several equities research analysts have issued reports on the stock. Leerink Partnrs downgraded shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 19th. Wedbush downgraded shares of Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 price target for the company. in a research report on Tuesday, March 19th. Truist Financial reiterated a “hold” rating and issued a $21.00 price target (up from $11.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. SVB Leerink reiterated a “market perform” rating and issued a $21.00 price target (up from $17.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $21.00 price target (up from $16.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th.

Fusion Pharmaceuticals Stock Performance

Shares of FUSN stock opened at $21.55 on Tuesday. The firm has a 50 day moving average price of $21.42 and a two-hundred day moving average price of $14.13. The company has a quick ratio of 10.64, a current ratio of 10.64 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $1.83 billion, a PE ratio of -15.18 and a beta of -0.69. Fusion Pharmaceuticals has a 12-month low of $2.31 and a 12-month high of $21.60.

Fusion Pharmaceuticals (NASDAQ:FUSN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Fusion Pharmaceuticals had a negative return on equity of 48.74% and a negative net margin of 4,136.55%. As a group, analysts predict that Fusion Pharmaceuticals will post -1.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC grew its stake in shares of Fusion Pharmaceuticals by 883.0% during the fourth quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock worth $28,000 after buying an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Fusion Pharmaceuticals by 2,064.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock worth $29,000 after buying an additional 2,869 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Fusion Pharmaceuticals by 66.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 13,920 shares of the company’s stock worth $297,000 after buying an additional 5,544 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $64,000. Finally, Bluefin Capital Management LLC bought a new stake in shares of Fusion Pharmaceuticals during the first quarter worth $213,000. 72.85% of the stock is owned by institutional investors.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.